HLA-C and neoplasm: Compared to CAR therapy, TCR therapy greatly expands the number of targetable tumor antigens by including all proteins presented on the cell surface in the context of MHC, by requiring less abundancy of the target antigen and by reducing the risk of cross-reactivity with healthy cells (51).